Shots: Sanofi to receive ~$353M including $2.25M up front and remaining as development, regulatory and commercial milestones as well as royalties on WW net sales of programs GBT gets exclusive […]readmore
Tags : Sickle Cell Disease
Shots: The Gates Foundation will provide funding support to discover and develop in vivo gene therapy for SCD. The alliance brings together Novartis drug discovery and gene therapy expertise with […]readmore
Shots: The US FDA’s approval is based on SUSTAIN study assessing Adakveo (5mg/kg, 2.5mg/kg) vs PBO in 198 patients in a ratio 1:1:1 aged ≥ 16yrs. with any genotype of […]readmore
Shots: The P-III RESET study involves assessing of Rivipansel (IV) vs PBO in 345 patients in a ratio (1:1) with SCD who were hospitalized for a VOC and required treatment […]readmore
Shots: The US FDA has accepted Novartis’ BLA and has granted Priority Review for crizanlizumab to prevent vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD) The FDA submission […]readmore